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We investigated if CLSI M27-A2 Candida species breakpoints for fluconazole MIC are valid when read at 24 h.
Analysis of a data set showed good correlation between 48- and 24-h MICs, as well as similar outcomes and
pharmacodynamic efficacy parameters, except for isolates in the susceptible dose-dependent category, such as
Candida glabrata.
Antifungal susceptibility testing for yeasts has been stan-
dardized since 1997 when the Clinical and Laboratory Stan-
dards Institute (CLSI) published the M27-A method (13). Sus-
ceptibility breakpoints for fluconazole and Candida spp. were
introduced after exhaustive epidemiological and clinical corre-
lation (12, 14). These breakpoints (susceptible, 8 g/ml; sus-
ceptible dose-dependent, 16 to 32 g/ml; resistant,64 g/ml)
have been validated in numerous studies over time (12, 14).
Currently the breakpoints are established for MICs read at
48 h. However, it is well known that MICs can often be read as
early as 24 h (13, 16), quality control limits for reading at 24 h
have been developed (3), and research has shown that early/
correct antifungal therapy has a positive impact on outcomes of
patients with candidemia (2, 7, 10). To provide clinicians with
useful susceptibility information sooner, we sought to determine
if reading the CLSI M27-A fluconazole MIC at 24 h would pro-
duce valid results when interpreted using the existing breakpoints.
Data set. The original data set used to create the 48-h break-
points has been described previously (12, 14). Briefly, it inte-
grates dosing and outcome information for 316 patients with
oropharyngeal and invasive disease treated with fluconazole
with antifungal susceptibility testing information for the 528
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TABLE 1. Correlation of 48 and 24-h fluconazole MICs (g/ml) in 505 Candida isolates
24-h MIC
(g/ml)
No. of isolates with 48-h MIC (g/ml)a:
%
0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 Total
0.0625 9 1 51 15 8 84 17
0.125 4 16 12 5 1 38 24
0.25 49 51 31 3 3 137 51
0.5 24 26 14 1 65 64
1 5 11 1 4 21 68
2 13 9 6 4 1 33 75
4 17 9 6 3 1 36 82
8 12 9 5 1 27 87
16 9 10 4 23 92
32 1 17 18 95
64 23 23 100
Total 9 5 116 102 75 42 28 27 28 20 53 505
% 2 3 26 46 61 69 75 80 86 90 100
a Numbers in bold indicate the number of isolates with the same exact MIC.
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isolates obtained from those patients. Antifungal susceptibility
testing was performed following the M27-A2 method, and
MICs were defined as the lowest concentration of drug pro-
ducing a prominent growth reduction (50%). MICs were read
at 24 and 48 h (11).
Twenty-four-hour MIC distribution and correlation with
48-h MICs. Table 1 shows the MIC distribution and correla-
tion for the 24- and 48-h MICs. As shown in Table 1, in
general, the majority of 24-h MICs tend to be 1 or 2 dilutions
lower than the corresponding 48-h MICs.
There is good correlation with an r2 of 0.50 and with 90% of
24-h MICs being within 2 dilutions of the corresponding 48-h
MIC. This corresponds to the accepted 2-dilution margin of
error of the method (13). Outliers are difficult to interpret, as
the trailing phenomenon could be playing a role (9). However,
when analyzing misclassification by the CLSI M23-A method-
ology (3), we overall found a very major error rate of 1.8%, a
major error rate of 0%, and a minor error rate of 9.7%, all
rates being within the tolerances required by M23-A.
Correlation with clinical outcomes. Table 2 shows the clin-
ical success rates (defined as resolution of Candida lesions and
symptoms for oropharyngeal disease and resolution of fever
and clearance of infected sites for invasive disease) of patients
treated with fluconazole doses of 100 mg/day grouped by 48-
and 24-h MICs for each patient-episode-isolate event. As seen
in Table 2, success rates are similar when using the M27-A2
breakpoints for MICs obtained after 48 and 24 h, with both
meeting the “90/60 rule” (13). Of note, the response rates for
24-h MICs in the susceptible dose-dependent category are
slightly lower than the 48-h rates. This is potentially related to
the classification of borderline isolates from resistant to sus-
ceptible dose-dependent due to the 1- or 2-dilution shift. Sim-
ilar results were observed when we analyzed the patients who
received 100 mg/day of fluconazole (data not shown).
Pharmacodynamic modeling. Human and animal data sug-
gest that the critical pharmacodynamic parameter for flucon-
azole is the area under the concentration-time curve/MIC ratio
(1, 8, 15). An area under the concentration-time curve/MIC
ratio of 25 to 50 accurately predicts therapeutic efficacy. This
correlates with success when using 400 mg/day for an isolate
with a MIC of 4 to 16 g/ml or 800 mg/day for one with a MIC
of 8 to 32 g/ml in a 70-kg adult. A surrogate of this measure
can be the dose/MIC ratio (1, 8, 15) if one assumes an average
weight and normal renal function for all patients in the data
set. Table 3 shows the success rates by dose/MIC ratios using
different fluconazole doses and the actual 48- and 24-h MICs.
The outcomes are similar for the two reading times, suggesting
comparable relevance of the pharmacodynamic parameters.
Conclusions. Reanalysis of the data set that was used to
create the original CLSI M27-A fluconazole susceptibility
breakpoints for Candida spp. shows good correlation between
48- and 24-h MICs. It also shows that applying the same break-
points to MICs obtained at 24 h as those applied to MICs
obtained at 48 h predicts therapeutic success as accurately as
do the 48-h MICs. Stated differently, the 24-h MIC reading
considered as a new test method shows a reasonable level of
similarity with the reference 48-h method. The caveat for this
is the reduced response rate seen in isolates classified as sus-
ceptible dose-dependent by the 24-h MIC. As discussed above,
this may be related to the reclassification of borderline-resis-
tant isolates in relation to the MIC shift. This is particularly
relevant for the species that is most likely to be affected by this
change due to its MIC distribution, Candida glabrata (12, 17).
Pharmacodynamic parameters predicting therapeutic success
are similar when using 48- and 24-h MIC data.
Multiple researchers have investigated 24-h fluconazole
readings in different data sets, showing similar results and
relevance (9, 13, 16). The same applies to other antifungal
susceptibility methods such as Eucast, disk diffusion, Etest, or
TREK Sensititre (4, 6, 9, 16), which in fact established 24-h
breakpoints early on and have shown very good correlation
with clinical outcomes and with the CLSI 48-h reference
method (4, 5, 15).
Although limited in size and in the amount of clinical, phar-
macological, and microbiological information, as well as by the
fact that invasive disease may be underrepresented, this data
set proved useful and successful in creating the original CLSI
M27-A breakpoints using 48-h MICs. These breakpoints have
undergone extensive subsequent validation and are widely ac-
cepted (12–14). This data set supports the use of the same
breakpoints with the CLSI M27-A2 procedure read after 24 h
of incubation, and as such this optional test methodology vari-
ation has been included in the latest version of the CLSI
M27-A3 method. As noted above, 24-h MICs of species that
typically have MICs in the higher end of the range, such as C.
glabrata, or MICs near the resistant endpoint, should be re-
ported with a cautionary note and/or not reported until the
48-h MIC is available. Further validation of this concept in
other data sets is warranted. Having the interpretative break-
point at 24 h will provide earlier clinically useful information to
clinicians treating patients with invasive candidiasis.
TABLE 2. Clinical success for patient-episode-isolate events treated
with 100 mg fluconazole/day by MIC interpretative category using
48- and 24-h MICs for fluconazole against Candida spp.
Breakpoint interpretative
category (MIC g/ml)
% Success (95% CIa; n)
48 h 24 h
Susceptible (8) 81 (74–87; 150) 82 (75–88; 167)
Susceptible dose-
dependent (16–32)
86 (67–96; 28) 55 (32–76; 22)
Resistant (64) 46 (30–63; 39) 39 (17–64; 18)
a CI, confidence interval.
TABLE 3. Clinical success for patient-episode-isolate events treated
with 100 mg fluconazole/day by dose/MIC ratios using 48- and
24-h MICs for fluconazole against Candida spp.
Dose/MIC ratio
% Success (95% CIa)
48 h 24 h
50 92 (89–94) 92 (89–95)
25 92 (89–94) 91 (88–93)
25 75 (67–81) 67 (57–76)
12.5 69 (59–77) 63 (50–74)
a CI, confidence interval.
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